Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claims are naming/active-ingredient statements (celecoxib) and are consistent with the provided label excerpt context that references CELEBREX and celecoxib; no medical safety or dosing claims were contradicted or misstated based on the supplied excerpts.
Category Scores
Accurate Statements
Celebrex’s generic name is celecoxib.
Supported by the provided labeling excerpts that repeatedly use CELEBREX and refer to celecoxib (e.g., contraindication section references celecoxib; CV thrombotic events section discusses celecoxib dose groups).
Celecoxib is the active ingredient in Celebrex.
Supported in the excerpts by explicit references to celecoxib in relation to CELEBREX dosing/risks (e.g., 'CELEBREX ... compared to placebo-treated patients' with dose arms described as CELEBREX 400 mg twice daily and CELEBREX 200 mg twice daily; sections attribute contraindications and risks to celecoxib).
Unsupported Statements
When filling a prescription for generic Celebrex, the label typically lists celecoxib.
The supplied FDA label excerpts do not address pharmacy labeling conventions for generic products.
Celebrex does not have multiple generic drug names.
The supplied FDA label excerpts do not address the existence or non-existence of multiple generic names.
Different manufacturers sell generic celecoxib, but the active ingredient name stays celecoxib.
The supplied FDA label excerpts do not discuss manufacturer variability or generic product naming across manufacturers.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims evaluated are limited to drug naming/active ingredient; no contraindications, warnings, dosing, or monitoring statements were made that would directly affect safety.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims about generic product labeling/manufacturer conventions are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Limit statements to what the label excerpts support (e.g., CELEBREX is associated with celecoxib) and avoid claims about how generic prescriptions/labels are typically displayed or about number of generic names/manufacturers unless supported by additional FDA labeling text provided in the audit.